fluorobenzenes has been researched along with Angiogenesis, Pathologic in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alsayed, A; He, C; Karginova, O; Lee, SS; Olopade, OI; Raoul, A; Weekley, CM; Wu, T | 1 |
| Chang, CC; Chuang, CL; Hsieh, HG; Huang, HC; Lee, FY; Lee, SD; Lee, WS; Lin, HC; Wang, SS | 1 |
| Hermonat, PL; Kang, BY; Khaidakov, M; Khan, JA; Mehta, JL; Wang, W | 1 |
| Bikow, J; Han, R; Keating, A; Lu, B; Parker, TG; Tao, W; Verma, S; Wang, C; Wang, Y; Wen, XY | 1 |
| Belenkov, IuN; Gabrusenko, SA; Kukharchuk, VV; Masenko, VP; Semenova, AE; Sergienko, IV | 1 |
1 trial(s) available for fluorobenzenes and Angiogenesis, Pathologic
| Article | Year |
|---|---|
[Effect of rosuvastatin therapy and myocardial revascularization on angiogenesis in coronary artery disease patients].
Topics: Anticholesteremic Agents; Cholesterol; Female; Fluorobenzenes; Hemodynamics; Humans; Male; Middle Aged; Myocardial Ischemia; Myocardial Revascularization; Neovascularization, Pathologic; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Rosuvastatin Calcium; Sulfonamides; Transforming Growth Factor beta1; Triglycerides; Vascular Endothelial Growth Factor A | 2007 |
4 other study(ies) available for fluorobenzenes and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis.
Topics: Animals; Apoptosis; Benzothiazoles; Bromobenzenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Copper; Copper Transport Proteins; Copper-Transporting ATPases; Female; Fluorobenzenes; Gene Expression Regulation, Neoplastic; Humans; Mice; Molecular Chaperones; Molybdenum; Neovascularization, Pathologic; Oxidative Stress; Paclitaxel; Small Molecule Libraries; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung.
Topics: Administration, Oral; Animals; Disease Models, Animal; Down-Regulation; Fluorobenzenes; Hemodynamics; Hepatopulmonary Syndrome; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lung; Male; Neovascularization, Pathologic; Pyrimidines; Rats; Rats, Sprague-Dawley; Reference Values; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2015 |
Statins and angiogenesis: is it about connections?
Topics: Angiogenesis Inhibitors; Animals; Antigens, CD; Aorta; Cadherins; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Neovascularization, Physiologic; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Umbilical Veins | 2009 |
Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer.
Topics: Angiogenesis Inhibitors; Animals; Drug Screening Assays, Antitumor; Fluorobenzenes; Humans; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tumor Cells, Cultured; Zebrafish | 2010 |